All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Rezolute stock crashes after sole pipeline candidate fails Phase III

Rezolute’s stock has crashed after its only pipeline product flopped in a Phase III trial. In the sunRIZE trial (NCT06208215),…
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4…
AI takes charge of data, but challenges linger

For years, one of the biggest barriers to effectively implementing artificial intelligence (AI) into clinical trial data management has been…
APAC’s rising stars beyond China

While China continues to dominate clinical trial activity across Asia-Pacific (APAC) and globally, other countries are rapidly emerging as significant…
Roche posts second Phase III win for oral SERD

Roche’s oral selective oestrogen receptor degrader (SERD) has reduced the risk of invasive disease recurrence or death by 30% in…

Dyne to seek accelerated approval of DMD drug on Phase I/II data

Dyne Therapeutics is seeking US accelerated approval of its Duchenne muscular dystrophy (DMD) drug after it met its endpoints in…
Kallyope’s migraine drug advances to pivotal trial

Kallyope is advancing its lead migraine drug to pivotal trials after it has shown to be competitive with marketed therapies…
UCB’s Fintepla led to nearly 50% seizure reduction in CDD patients

UCB’s Fintepla (fenfluramine) has been associated with a nearly 50% reduction in countable motor seizure frequency (CMSF) in adult and…
AI can reduce R&D costs to alleviate looming patent cliff pressures

AI will be a useful tool in reducing R&D costs to help alleviate some of the pain pharma will feel…
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints

Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of its Duchenne muscular dystrophy (DMD) cell…